Bexarotene

ApprovedCompleted
0 watching 0 views this week๐Ÿ”ฅ Hot
80
Hype Score

Development Stage

โœ“
Pre-clinical
โœ“
Phase 1
โœ“
Phase 2
โœ“
Phase 3
5
Approved
Indication / Disease

Refractory Cutaneous T-cell Lymphoma

Conditions

Refractory Cutaneous T-cell Lymphoma

Trial Timeline

Jan 6, 2010 โ†’ Feb 20, 2014

About Bexarotene

Bexarotene is a approved stage product being developed by Bausch Health for Refractory Cutaneous T-cell Lymphoma. The current trial status is completed. This product is registered under clinical trial identifier NCT01007448. Target conditions include Refractory Cutaneous T-cell Lymphoma.

Hype Score Breakdown

Clinical
30
Activity
20
Company
5
Novelty
10
Community
12

Clinical Trials (1)

NCT IDPhaseStatus
NCT01007448ApprovedCompleted